If you would like more information on Liver, Bile Duct and Gallbladder Cancer Clinical Trials offered at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, please contact: 410-955-8964, Option #2.
Current trial listing:
J18118 - The effect of CTLA4/PDL-1 Blockade following drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with intermediate stage of HCC using Durvalumab (MEDI4736) and Tremelimumab
J19140 - A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with Nivolumab and Ipilimumab for patients with fibrolamellar hepatocellular carcinoma
J2003 - An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid encoded IL 12 (INO-9012) in Combination with Pembrolizumab (MK-3475) in Subjects with Advanced Hepatocellular Carcinoma
J2007 - A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors
J20121 - Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients with Potentially Resectable Hepatocellular Carcinoma (HCC)
J2121 - A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK 1308A (Co-formulated MK 1308/MK 3475) in Combination with Lenvatinib (E7080/MK 7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma.
Biliary Tract Cancers: Cholangiocarcinoma/Bile duct Cancer/Gallbladder Cancer
J19108 - A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824 (bintrafusp alfa) as First-line Treatment of Biliary Tract Cancer
J2007 - A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors.
J2031 - J2031: A Phase II Study of durvalumab (MEDI4736) in combination with a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients with Intrahepatic Cholangiocarcinoma.
J2075 - An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements. NCT04507503
J2089 - A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations (LOXO-IDH-20002)
ETCTN10129 - A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors.
ETCTN10222 - A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors.